Celltrion Chairman Seo Jung-jin says the South Korean company will spend about $33 billion over a decade on its biologics and pharma businesses.

Gilead's Truvada for PrEP is only getting to about 10% of people who could benefit, according to testimony Thursday.

The new endorsement of Celgene's Revlimid from England's cost watchdog NICE may not help calm fears about BMS' $74 billion buyout.

EMS Pharma, whose sister company Novamed bought Takeda’s Multilab last year, is reportedly the front-runner in the bidding process.

Ahead of an aesthetics market battle between Evolus' Jeuveau and Allergan's Botox, Evolus hosted doctors at a conference in Cancun.

Since Nestlé took full control of Galderma in 2014, its skin health unit never really lived up to expectations. And now, the company is bailing.

GlaxoSmithKline will unload an API plant to Thermo Fisher Scientific for €90 million. The U.S. company says it is glad to get it.

Civica Rx, a hospital group committed to manufacturing its own drugs, has picked the first drugs it will make and the contractor to make them.

With Novartis approaching jury trial for an alleged kickback scheme to docs, the feds seemed to have the company where they wanted it. Or maybe not.